Camlin Fine Sciences Limited (CFS) has signed an agreement to acquire a majority stake in Vinpai S.A., a French company specialising in functional ingredients derived from algae, plants, minerals, and fibers.
The deal will be carried out through a share swap and a cash offer.
CFS will initially acquire 78.68% of Vinpai’s outstanding share capital from its founders and other major shareholders. Instead of paying in cash, CFS will issue new ordinary shares to the sellers, with the price calculated in line with SEBI’s ICDR Regulations, 2018.
Alongside the acquisition, CFS will invest €3.3 million in Vinpai through listed secured convertible bonds. These bonds will be converted into ordinary equity shares after the acquisition, increasing CFS’s stake further.
Once the majority acquisition and bond conversion are completed, CFS will initiate a public tender offer to buy the remaining Vinpai shares at €3.60 per share. If this results in CFS owning more than 90%, a squeeze-out process under French law could follow, leading to full ownership.
The deal is subject to regulatory and shareholder approvals. The Autorité des marchés financiers (AMF), the French financial regulator, must approve the tender offer. CFS aims to complete the transaction by June 30, 2025.
The acquisition expands CFS’s presence in natural ingredients. However, the impact on its valuation and future strategy remains to be seen.
Camlin Fine Sciences Ltd shares were trading at ₹162.00, up ₹0.99 (0.61%) today (as of Feb 25, 10:10 AM), with a 36.29% gain over the past month and a 57.76% rise in the past six months.
Vinpai was founded in 2011 and focuses on providing natural ingredient alternatives for the food, cosmetics, and nutraceutical industries. It has developed over 3,500 formulations and operates from two locations in France.
Recent financials:
The company went public on Euronext Growth Paris in July 2023.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Feb 25, 2025, 2:54 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
